FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3045129059> ?p ?o ?g. }

• W3045129059 endingPage "1190" @default.
• W3045129059 startingPage "1180" @default.
• W3045129059 abstract "ObjectiveVery few cost-utility analyses have either evaluated direct-acting antivirals (DAAs) on hepatitis C virus (HCV) genotype 6 patients or undertaken societal perspective. Recently, DAAs have been introduced into the Vietnamese health insurance drug list for chronic hepatitis C (CHC) treatment without empirical cost-effectiveness evidence. This study was conducted to generate these data on DAAs among CHC patients with genotypes 1 and 6 in Vietnam.MethodsA hybrid decision-tree and Markov model was employed to compare costs and quality-adjusted life-years (QALYs) of available DAAs, including (1) sofosbuvir/ledipasvir, (2) sofosbuvir/velpatasvir, and (3) sofosbuvir plus daclatasvir, with pegylated-interferon plus ribavirin (PR). Primary data collection was conducted in Vietnam to identify costs and utility values. Incremental cost-effectiveness ratios were estimated from societal and payer perspectives. Uncertainty and scenario analyses and value of information analyses were performed.ResultsAll DAAs were cost-saving as compared with PR in CHC patients with genotypes 1 and 6 in Vietnam, and sofosbuvir/velpatasvir was the most cost-saving regimen, from both societal and payer perspectives. From the societal perspective, DAAs were associated with the increment of quality-adjusted life-years by 1.33 to 1.35 and decrement of costs by $6519 to $7246. Uncertainty and scenario analyses confirmed the robustness of base-case results, whereas the value of information analyses suggested the need for further research on relative treatment efficacies among DAA regimens.ConclusionsAllocating resources for DAA treatment for HCV genotype 1 and 6 is surely a rewarding public health investment in Vietnam. It is recommended that the government rapidly scale up treatment and enable financial accessibility for HCV patients." @default.
• W3045129059 created "2020-07-29" @default.
• W3045129059 creator A5030389292 @default.
• W3045129059 creator A5042553941 @default.
• W3045129059 creator A5052551841 @default.
• W3045129059 creator A5056464791 @default.
• W3045129059 creator A5065283360 @default.
• W3045129059 creator A5074284739 @default.
• W3045129059 date "2020-09-01" @default.
• W3045129059 modified "2023-10-16" @default.
• W3045129059 title "Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam" @default.
• W3045129059 cites W1499961110 @default.
• W3045129059 cites W1578809675 @default.
• W3045129059 cites W1588369580 @default.
• W3045129059 cites W1592252435 @default.
• W3045129059 cites W1603283902 @default.
• W3045129059 cites W1895397534 @default.
• W3045129059 cites W1980154502 @default.
• W3045129059 cites W2002345728 @default.
• W3045129059 cites W2007682914 @default.
• W3045129059 cites W2042063943 @default.
• W3045129059 cites W2072314608 @default.
• W3045129059 cites W2078799829 @default.
• W3045129059 cites W2084119969 @default.
• W3045129059 cites W2115025298 @default.
• W3045129059 cites W2126621933 @default.
• W3045129059 cites W2139944544 @default.
• W3045129059 cites W2160626977 @default.
• W3045129059 cites W2162317388 @default.
• W3045129059 cites W2196193147 @default.
• W3045129059 cites W2229638189 @default.
• W3045129059 cites W2325297898 @default.
• W3045129059 cites W2473786944 @default.
• W3045129059 cites W2501094045 @default.
• W3045129059 cites W2512251569 @default.
• W3045129059 cites W2512634327 @default.
• W3045129059 cites W2520731166 @default.
• W3045129059 cites W2560002598 @default.
• W3045129059 cites W2562480176 @default.
• W3045129059 cites W2589621872 @default.
• W3045129059 cites W2607312384 @default.
• W3045129059 cites W2750519500 @default.
• W3045129059 cites W2758719604 @default.
• W3045129059 cites W2777014851 @default.
• W3045129059 cites W2784193918 @default.
• W3045129059 cites W2793883945 @default.
• W3045129059 cites W2898940207 @default.
• W3045129059 cites W2985629702 @default.
• W3045129059 cites W2990963086 @default.
• W3045129059 cites W3013295362 @default.
• W3045129059 doi "https://doi.org/10.1016/j.jval.2020.03.018" @default.
• W3045129059 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7491253" @default.
• W3045129059 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32940236" @default.
• W3045129059 hasPublicationYear "2020" @default.
• W3045129059 type Work @default.
• W3045129059 sameAs 3045129059 @default.
• W3045129059 citedByCount "12" @default.
• W3045129059 countsByYear W30451290592020 @default.
• W3045129059 countsByYear W30451290592021 @default.
• W3045129059 countsByYear W30451290592022 @default.
• W3045129059 countsByYear W30451290592023 @default.
• W3045129059 crossrefType "journal-article" @default.
• W3045129059 hasAuthorship W3045129059A5030389292 @default.
• W3045129059 hasAuthorship W3045129059A5042553941 @default.
• W3045129059 hasAuthorship W3045129059A5052551841 @default.
• W3045129059 hasAuthorship W3045129059A5056464791 @default.
• W3045129059 hasAuthorship W3045129059A5065283360 @default.
• W3045129059 hasAuthorship W3045129059A5074284739 @default.
• W3045129059 hasBestOaLocation W30451290591 @default.
• W3045129059 hasConcept C112930515 @default.
• W3045129059 hasConcept C126322002 @default.
• W3045129059 hasConcept C159047783 @default.
• W3045129059 hasConcept C184834754 @default.
• W3045129059 hasConcept C2522874641 @default.
• W3045129059 hasConcept C2775999097 @default.
• W3045129059 hasConcept C2776408679 @default.
• W3045129059 hasConcept C2776455275 @default.
• W3045129059 hasConcept C2776461080 @default.
• W3045129059 hasConcept C2776979040 @default.
• W3045129059 hasConcept C2778390639 @default.
• W3045129059 hasConcept C2780040827 @default.
• W3045129059 hasConcept C2781413609 @default.
• W3045129059 hasConcept C3019080777 @default.
• W3045129059 hasConcept C71924100 @default.
• W3045129059 hasConceptScore W3045129059C112930515 @default.
• W3045129059 hasConceptScore W3045129059C126322002 @default.
• W3045129059 hasConceptScore W3045129059C159047783 @default.
• W3045129059 hasConceptScore W3045129059C184834754 @default.
• W3045129059 hasConceptScore W3045129059C2522874641 @default.
• W3045129059 hasConceptScore W3045129059C2775999097 @default.
• W3045129059 hasConceptScore W3045129059C2776408679 @default.
• W3045129059 hasConceptScore W3045129059C2776455275 @default.
• W3045129059 hasConceptScore W3045129059C2776461080 @default.
• W3045129059 hasConceptScore W3045129059C2776979040 @default.
• W3045129059 hasConceptScore W3045129059C2778390639 @default.
• W3045129059 hasConceptScore W3045129059C2780040827 @default.
• W3045129059 hasConceptScore W3045129059C2781413609 @default.
• W3045129059 hasConceptScore W3045129059C3019080777 @default.

• next